Envoy Medical

Envoy Medical FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Envoy Medical (COCH) as of Nov 2, 2026 is 77.37 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 91.03 % — a change of -15.00% (lower).

FCF Conversion

77.37 %

YoY

-15.00%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Envoy Medical is 2025 77.37 % . FCF Conversion Rate (FCF/EBITDA) of Envoy Medical was 2024 91.03 % . It decreases by -15.00% lower compared to the previous year.

The Envoy Medical FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2020
0.00 USD
Jan 1, 2021
81.39 USD
Jan 1, 2022
56.67 USD
Jan 1, 2023
57.63 USD
Jan 1, 2024
91.03 USD
Jan 1, 2025
77.37 USD
The Envoy Medical FCF Conversion history
YEARFCF ConversionYoY
77.37 %-15.00%
91.03 %+57.95%
57.63 %+1.70%
56.67 %-30.38%
81.39 %—
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Envoy Medical Stock analysis

What does Envoy Medical do? Envoy Medical Inc generates revenue through its portfolio of hearing health solutions including hearing aids, middle ear implants, bone conduction devices, and cochlear implants. The company's Esteem is a fully implanted active middle ear implant targeting adults with moderate to severe sensorineural hearing loss. Bone conduction devices feature an external component paired with a surgically implanted fixture behind the ear, offering amplification without ear molds. Hearing aids serve patients with mild to moderate hearing loss, while cochlear implants address moderate-to-profound sensorineural hearing loss. These products are sold to healthcare providers and patients seeking advanced hearing solutions within the hearing loss spectrum. The company's business model focuses on providing medical technologies that shift industry paradigms, with products designed for different severity levels of hearing loss. Hearing aids target mild to moderate cases, while cochlear implants and Esteem address more severe conditions. Bone conduction devices specifically eliminate the need for ear molds by using bone conduction technology. All solutions are positioned to serve both providers and patients requiring specialized hearing devices across the hearing loss spectrum. Envoy Medical Inc's revenue streams come from direct sales of its hearing devices to healthcare providers who then serve patients. The company's product range spans from non-invasive hearing aids for mild cases to fully implanted solutions like Esteem for severe hearing loss. Each product category targets specific patient segments based on hearing loss severity, ensuring tailored solutions for different needs within the hearing health market. Envoy Medical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Envoy Medical stock

FCF Conversion Rate (FCF/EBITDA) of Envoy Medical is 77.37 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Envoy Medical changed from 91.03 % to 77.37 %, representing a -15.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Envoy Medical since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Envoy Medical with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Envoy Medical

All Key Metrics — Envoy Medical